Market Insight – Finding cash in unconventional places
This article was originally published in Scrip
A perfect storm of challenges is thrashing clinical development. There is increased pressure to replace ageing blockbusters amid an environment of rising development costs and shrinking budgets. The usual response of reducing costs through productivity gains and outsourcing initiatives is no longer enough to fund pipeline development. Now, the pharmaceutical industry is on the cusp of a new model. Innovators are increasing development budgets by using alternative financing. They are learning from the biotech community, which has relied on alternative financing as a way of life.
You may also be interested in...
One year after acquiring Piramal's Domestic Formulations business in a deal that made it India's largest pharmaceutical player, Abbott remains confident about its growth prospects in India, where it hopes to be generating $2.5 billion in sales by 2020. But facing fierce competition from domestic firms, Abbott isn't about to get complacent, Michael Warmuth, senior VP of the company's Established Products Division, tells Pete Chan. This article is part of the 2011 Scrip Asia 100.
Asia life science-focused VC firms*
Roche is overhauling its cost structure to produce a leaner organisation better equipped to focus on the business of pharmaceutical innovation. It is also investing heavily in China, turning its Shanghai operations into a centre for everything from commercial manufacturing and research to partnering, licensing and strategic planning. Pascal Soriot, chief operating officer of Roche Pharmaceuticals, speaks to Pete Chan in an exclusive interview.